• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Mainz Biomed N.V.

    5/15/25 3:44:59 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MYNZ alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    MAINZ BIOMED N.V.

    (Name of Issuer)


    Ordinary Shares, nominal value of 0.01 per share

    (Title of Class of Securities)


    N5436L119

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    N5436L119


    1Names of Reporting Persons

    Armistice Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    324,821.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    324,821.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    324,821.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    N5436L119


    1Names of Reporting Persons

    Steven Boyd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    324,821.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    324,821.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    324,821.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    MAINZ BIOMED N.V.
    (b)Address of issuer's principal executive offices:

    ROBERT KOCH STRASSE 50, MAINZ, Germany, 55129
    Item 2. 
    (a)Name of person filing:

    Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
    (b)Address or principal business office or, if none, residence:

    Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
    (c)Citizenship:

    Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
    (d)Title of class of securities:

    Ordinary Shares, nominal value of 0.01 per share
    (e)CUSIP No.:

    N5436L119
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    324,821
    (b)Percent of class:

    9.99  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    324,821

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    324,821 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Armistice Capital, LLC
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd - Managing Member
    Date:05/15/2025
     
    Steven Boyd
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd
    Date:05/15/2025
    Exhibit Information

    JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

    Get the next $MYNZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYNZ

    DatePrice TargetRatingAnalyst
    2/14/2025$14.00Buy
    Maxim Group
    11/25/2024Buy → Neutral
    H.C. Wainwright
    11/21/2023Overweight → Neutral
    Cantor Fitzgerald
    6/21/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $MYNZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

      Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it intends to provide an interim read out of its eAArly DETECT 2 feasibility study by the end of summer 2025. The study is evaluating the Company's next-generation colorectal cancer (CRC) screening test that integrates Mainz Biomeds proprietary mRNA biomarkers, an AI-devel

      5/16/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Enters into Technology Partnership with EDX Medical Group

      BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t

      4/29/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

      BERKELEY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments of the first quarter of 2025, and provided an outlook on its path to FDA premarket approval.   During the first quarter of 2025: Path to FDA premarket approval: The Company enrolled the first patient into its feasibility study eAArly DETECT 2, which evaluates the Mainz Biomed's next-generation colorectal cancer (CRC) test, integrating a portfolio of proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test. The study is

      4/28/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Mainz Biomed B.V. with a new price target

      Maxim Group initiated coverage of Mainz Biomed B.V. with a rating of Buy and set a new price target of $14.00

      2/14/25 8:10:14 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed B.V. downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Mainz Biomed B.V. from Buy to Neutral

      11/25/24 7:48:30 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed B.V. downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Mainz Biomed B.V. from Overweight to Neutral

      11/21/23 7:33:52 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Financials

    Live finance-specific insights

    See more
    • Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program

      Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property ("IP") for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorec

      2/21/23 3:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers

      Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer Biomarkers Demonstrated Unique Ability to Identify Curable Precancerous Colonic Polyps as well as Curable Early-Stage Colorectal Cancer BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. ("TTS") to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert,

      1/5/22 3:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Leadership Updates

    Live Leadership Updates

    See more
    • Mainz Biomed Enters into Technology Partnership with EDX Medical Group

      BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t

      4/29/25 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

      BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the addition of Petra Smeltzer Starke as a Brand Ambassador for the Company. As Brand Ambassador she will help the Company in the development and dissemination of messaging focused on the importance of early detection of colorectal cancer. "We are excited about Petra joining our team as Brand Ambassador. Her broad and deep experience will be invaluable to us as we bring our next generation colorectal cancer screening product to market, with the

      9/18/24 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations

      Former Natera Manager will oversee all aspects of sales and support in EMEA, ensuring the continued commercialization of ColoAlert® across the region BERKELEY, Calif. and MAINZ, Germany, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is proud to announce the appointment of Tarrin Khairi-Taraki as Vice President of Commercial Operations, EMEA. Tarrin will play a pivotal role in steering Mainz Biomed's continued success, focusing on the commercialization of its flagship product, ColoAlert® — a highly effective and user-friendly at-home detection test f

      10/26/23 8:01:00 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYNZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MYNZ
    SEC Filings

    See more
    • Amendment: SEC Form SC 13G/A filed by Mainz Biomed N.V.

      SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

      10/7/24 4:47:27 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Mainz Biomed N.V. (Amendment)

      SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

      2/13/24 2:39:04 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Mainz Biomed N.V.

      SC 13G - MAINZ BIOMED N.V. (0001874252) (Subject)

      3/1/23 6:38:43 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mainz Biomed N.V.

      SCHEDULE 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

      5/15/25 3:44:59 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form F-1/A filed by Mainz Biomed N.V.

      F-1/A - MAINZ BIOMED N.V. (0001874252) (Filer)

      5/14/25 4:20:36 PM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form F-1 filed by Mainz Biomed N.V.

      F-1 - MAINZ BIOMED N.V. (0001874252) (Filer)

      5/14/25 8:43:39 AM ET
      $MYNZ
      Biotechnology: Pharmaceutical Preparations
      Health Care